Market Cap
$20.2M
TCRX
TScan Therapeutics, Inc.
$0.3273 ▲ +2.92%
Prev close $0.3180Market cap$20.2M
ConsensusBuy
12-mo target$1.00 (+205.5%)
▲ Bullish
Analyst conviction 8/10
High Impact Filing (7/10)11 New Institutional Positions Biotech & Drug Discovery
Snapshot
The big-picture read on TCRX right now — valuation, ownership and activity at a glance.
Cap Size
Nano Cap
Analyst Consensus
Strong Buy (77%)
Inst. Holders
37 funds
Inst. Value
$15.9M
Inst. Activity
11 buys / 2 sells
SEC Reports
8
Press Releases
2
Price chart 30d -14.1%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 22, 2026 short_volume
Sep 11, 2026 SEC Short Volume: TCRX — 66.3% short (0.5M / 0.7M)
Short: 465,705 | Exempt: 150 | TRF Vol: 702,624 | Short Ratio: 66.3% | Off-exchange volume (dark poo
TScan Therapeutics filed an 8-K on September 11, 2026, disclosing a retention program approved by the Compensation Commi
8-K — Impact 5/10
TScan Therapeutics announced a drastic strategic reorganization: a 75% workforce reduction, termination of its CFO and C
8-K — Impact 7/10
TScan Therapeutics disclosed that Amgen terminated their Research Collaboration and License Agreement for Crohn's diseas
8-K — Impact 7/10
Jun 30, 2026 Inst.
JACOBS LEVY EQUITY MANAGEMENT, — ADD
1,049,806 shares ($1.0M)
Jun 30, 2026 Inst.
Jun 22, 2026 Press CITADEL ADVISORS LLC — DOUBLED
1,009,107 shares ($989.0K)
TScan Therapeutics presented positive Phase 1 Cohort C data for TSC-101, showing 11 of 14 patients achieved complete don
Impact 7/10
May 20, 2026 Insider
Gruia Gabriela was granted 67,000 shares
Director
Analyst ratings buy % +0.0%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
77% rate it Buy or better · 13 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Sep 8, 2026 | HC Wainwright & Co. | DOWNGRADE | Neutral | 43% |
| Sep 3, 2026 | Wedbush | DOWNGRADE | Neutral | 57% |
| Sep 2, 2026 | Needham | DOWNGRADE | Hold | 50% |
| Aug 12, 2026 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| Jun 23, 2026 | Wedbush | REITERATE | Outperform | 57% |
| Jun 23, 2026 | Needham | REITERATE | Buy | 50% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 3 | 7 | 3 | 0 | 0 | 77% | |
| Aug 1, 2026 | 3 | 7 | 3 | 0 | 0 | 77% | |
| Jul 1, 2026 | 3 | 7 | 3 | 0 | 0 | 77% | |
| Jun 1, 2026 | 3 | 7 | 3 | 0 | 0 | 77% | |
| May 1, 2026 | 3 | 7 | 3 | 0 | 0 | 77% | |
| Apr 1, 2026 | 3 | 7 | 3 | 0 | 0 | 77% | |
| Mar 1, 2026 | 3 | 7 | 3 | 0 | 0 | 77% | |
| Feb 1, 2026 | 3 | 7 | 3 | 0 | 0 | 77% |
Price targets
Where 2 covering analysts think TCRX trades over the next 12 months.
$1.00 +205.5% upside Strong Buy
Current$0.3273 Low$1.00 Median$1.00 High$1.00 2 analysts
$1.00$1.00
Analyst rating Hold· 2.6/5 as of Oct 2, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
8 SEC filing reports analyzed · 1 bullish, 4 bearish, 0 mixed, 3 neutral · avg impact 5.5/10.Plus 2 press releases.
NEUTRAL8-K5/10
TScan Therapeutics filed an 8-K on September 11, 2026, disclosing a retention program approved by th
Sep 11, 2026
BEARISH8-K7/10
TScan Therapeutics announced a drastic strategic reorganization: a 75% workforce reduction, terminat
Sep 2, 2026
BEARISH8-K7/10
TScan Therapeutics disclosed that Amgen terminated their Research Collaboration and License Agreemen
Aug 18, 2026
BEARISH8-K6/10
TScan Therapeutics reported Q2 2026 results with revenue of $1.1M (down 66% YoY from $3.1M) and a ne
Aug 12, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 22, 2026
short_volume
Short Volume: TCRX — 66.3% short (0.5M / 0.7M)
Short: 465,705 | Exempt: 150 | TRF Vol: 702,624 | Short Ratio: 66.3% | Off-exchange volume (dark pool + OTC)
Sep 15, 2026
short_interest_report
Short Interest: TCRX up 30% to 2.3M shares
Settlement 2026-09-15 | Days to cover: 1.16 | ≈3.59% of shares outstanding (est.)
Sep 10, 2026
short_volume
Short Volume: TCRX — 67.7% short (0.4M / 0.6M)
Short: 386,030 | Exempt: 168 | TRF Vol: 570,189 | Short Ratio: 67.7% | Off-exchange volume (dark pool + OTC)
Sep 9, 2026
short_volume
Short Volume: TCRX — 66.0% short (0.4M / 0.5M)
Short: 362,653 | Exempt: 80,909 | TRF Vol: 549,766 | Short Ratio: 66.0% | Off-exchange volume (dark pool + OTC)
Sep 8, 2026
short_volume
Short Volume: TCRX — 61.0% short (0.7M / 1.2M)
Short: 712,257 | Exempt: 31,256 | TRF Vol: 1,167,309 | Short Ratio: 61.0% | Off-exchange volume (dark pool + OTC)
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-0.18 | $-0.23–$-0.08 | 34.8% | +16.1% | 1↑ 2↓ | $0.0B | 4 |
| Next Q | $-0.15 | $-0.21–$-0.09 | 15.3% | +29.1% | 3↑ 0↓ | $0.0B | 4 |
| Current FY | $-0.78 | $-0.89–$-0.62 | 22.3% | +10.9% | 1↑ 2↓ | $0.0B | 4 |
| Next FY | $-0.57 | $-1.03–$-0.27 | 26.4% | +38.8% | 3↑ 1↓ | $0.0B | 4 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-0.182 | — |
| 7d ago | $-0.182 | — |
| 30d ago | $-0.217 | +0.035 |
| 60d ago | $-0.215 | +0.033 |
| 90d ago | $-0.215 | +0.033 |
Institutional ownership
Which big funds own TCRX (from quarterly 13F filings) and who is adding or trimming.
37 institutional holders with $15.9M total value (16,341,403 shares) as of 2026-Q2. Top holders: ROYAL, BAKER, VANGUARD. Net buying activity: 11 institutions added/increased vs 2 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| ROYAL BANK OF CANADA | 78 | $0.00 | 0.0% | — |
| BAKER BROS. ADVISORS LP | 2,784,792 | $2.7M | 17.2% | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 2,158,831 | $2.1M | 13.3% | — |
| TWO SIGMA INVESTMENTS, LP | 1,949,604 | $1.9M | 12.1% | ADD +55.3% |
| RENAISSANCE TECHNOLOGIES LLC | 1,326,799 | $1.3M | 8.2% | ADD +37.5% |
| MILLENNIUM MANAGEMENT LLC | 1,163,611 | $1.1M | 7.2% | DOUBLED +261.8% |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 1,049,806 | $1.0M | 6.5% | ADD +29.9% |
| CITADEL ADVISORS LLC | 1,009,107 | $989.0K | 6.2% | DOUBLED +216.9% |
| BlackRock, Inc. | 994,654 | $974.9K | 6.1% | TRIM -46.0% |
| MARSHALL WACE, LLP | 687,364 | $673.6K | 4.2% | DOUBLED +189.6% |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| JACOBS LEVY EQUITY MANAGEMENT, INC | ADD | 808,356 | 1,049,806 | +29.9% | $1.0M |
| CITADEL ADVISORS LLC | DOUBLED | 318,411 | 1,009,107 | +216.9% | $989.0K |
| BlackRock, Inc. | TRIM | 1,840,952 | 994,654 | -46.0% | $974.9K |
| MARSHALL WACE, LLP | DOUBLED | 237,346 | 687,364 | +189.6% | $673.6K |
| D. E. Shaw & Co., Inc. | ADD | 319,587 | 548,402 | +71.6% | $537.5K |
| JANE STREET GROUP, LLC | ADD | 144,421 | 241,493 | +67.2% | $236.7K |
| NORTHERN TRUST CORP | ADD | 97,448 | 138,778 | +42.4% | $136.0K |
| GOLDMAN SACHS GROUP INC | ADD | 37,267 | 70,514 | +89.2% | $69.1K |
| AMERIPRISE FINANCIAL INC | ADD | 52,635 | 69,487 | +32.0% | $68.1K |
| UBS Group AG | DOUBLED | 32,484 | 68,873 | +112.0% | $67.5K |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
6 insiders, 6 transactions. Net $0.00 — $0.00 bought, $0.00 sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 20, 2026 | Gruia Gabriela | Director | AWARD | 67,000 | — | — |
| May 20, 2026 | Dorton Katina | Director | AWARD | 67,000 | — | — |
| May 20, 2026 | Klencke Barbara | Director | AWARD | 67,000 | — | — |
| May 20, 2026 | Woods Keith | Director | AWARD | 67,000 | — | — |
| May 20, 2026 | Nicholson Garry A | Director | AWARD | 67,000 | — | — |
| May 20, 2026 | BAKER BROS. ADVISORS LP | Director | AWARD | 67,000 | — | — |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for TCRX.
Shares short
2,280,163
Settlement Sep 15, 2026
Change vs prior
+30.3%
Semi-monthly cycle
Days to cover
1.2
At avg daily volume
Of shares outstanding
≈3.6%
Estimate — not % of float
All TCRX filing & press-release reports (10)
- 8-K reportSep 11, 2026
- 8-K reportSep 2, 2026
- 8-K reportAug 18, 2026
- 8-K reportAug 12, 2026
- PRESS-RELEASE reportAug 12, 2026
- 8-K reportJul 3, 2026
- PRESS-RELEASE reportJun 22, 2026
- 8-K reportMay 6, 2026
- 8-K reportApr 2, 2026
- PRESS-RELEASE reportMar 4, 2026